UnknownNot Applicable

UltraShape Device for Thigh Fat and Circumference Reduction vs. Control

United States60 participantsStarted 2015-06

Plain-language summary

UltraShape Device for Thigh Fat and Circumference Reduction: Prospective, blinded, one arm, baseline-controlled clinical study for the evaluation of the UltraShape treatment for non-invasive fat and circumference reduction.

Who can participate

Age range18 Years – 60 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Signed informed consent to participate in the study.
✓. Female and male subjects,18 and 60 years of age at the time of enrolment
✓. Fitzpatrick Skin Type I to VI.
✓. Fat thickness of at least 1.5 cm in the treated area (measured by calibrated caliper).
✓. BMI interval: BMI in range of 22- 30 (normal to overweight, but not obese).
✓. If female, not pregnant or lactating, must be either post-menopausal, surgically sterilized, or using a medically acceptable form of birth control at least 3 months prior to enrollment (i.e., oral contraceptives, contraceptive implant, barrier methods with spermicide or abstinence).
✓. In addition, negative urine pregnancy test as tested before each treatment and at the last follow-up visit for women with child-bearing potential (e.g. not menopause).
✓. General good health confirmed by medical history and skin examination of the treated area.

Exclusion criteria

✕. History of hypertension, ischemic heart disease, valvular heart disease, congestive heart failure, pacemaker/defibrillator, abdominal aortic aneurism
✕. Known hyperlipidemia, diabetes mellitus, hepatitis, liver disease, HIV positive status, blood coagulopathy or excessive bleeding, autoimmune or connective tissue disease
✕. Having or undergoing any form of treatment for active cancer, or having a history of skin cancer or any other cancer in the areas to be treated, including presence of malignant or pre-malignant pigmented lesions
✕. Having any active electrical implant anywhere in the body, such as a pacemaker or an internal defibrillator
✕. Having a permanent implant in the treated area, such as metal plates or an injected chemical substance such as silicone
✕. Having undergone any other surgery in the treated areas within 12 months of treatment or during the study, including liposuction
✕. Previous body contouring procedures in the treatment area within 12 months
✕. History of skin disease in the treatment area, known tendency to form keloids or poor wound healing

What they're measuring

evaluate the efficacy of the UltraShape device by evaluating the non-invasive fat and circumference reduction

Timeframe: 8 weeks up to 20 weeks

Trial details

NCT IDNCT02488083

SponsorSyneron Medical

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2016-12

Contact for this trial

Robert Weiss, MD

410-666-3960

View on ClinicalTrials.gov More Unwanted Thigh Fat trials